Xingcheng Chen

1.2k total citations
18 papers, 819 citations indexed

About

Xingcheng Chen is a scholar working on Cell Biology, Molecular Biology and Oncology. According to data from OpenAlex, Xingcheng Chen has authored 18 papers receiving a total of 819 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cell Biology, 8 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Xingcheng Chen's work include Hippo pathway signaling and YAP/TAZ (16 papers), Microtubule and mitosis dynamics (9 papers) and Cancer-related Molecular Pathways (3 papers). Xingcheng Chen is often cited by papers focused on Hippo pathway signaling and YAP/TAZ (16 papers), Microtubule and mitosis dynamics (9 papers) and Cancer-related Molecular Pathways (3 papers). Xingcheng Chen collaborates with scholars based in United States and China. Xingcheng Chen's co-authors include Jixin Dong, Yuanhong Chen, Seth Stauffer, Shuping Yang, John S. Davis, Jin Zhou, Chunbo He, Guohua Hua, Xiangmin Lv and Cheng Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Molecular and Cellular Biology.

In The Last Decade

Xingcheng Chen

16 papers receiving 811 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xingcheng Chen United States 13 517 476 167 111 66 18 819
Andrea Tagliaferro Canada 12 226 0.4× 995 2.1× 268 1.6× 165 1.5× 53 0.8× 13 1.3k
Xinyan Ji China 10 406 0.8× 365 0.8× 110 0.7× 75 0.7× 36 0.5× 11 631
Sue Penrhyn-Lowe United Kingdom 5 430 0.8× 520 1.1× 281 1.7× 111 1.0× 23 0.3× 8 892
M. Verónica Ponce-Castañeda Mexico 12 72 0.1× 388 0.8× 300 1.8× 99 0.9× 63 1.0× 22 647
Jia-Xi Mao China 7 93 0.2× 733 1.5× 96 0.6× 110 1.0× 34 0.5× 16 935
Paul‐Joseph Aspuria United States 13 84 0.2× 547 1.1× 242 1.4× 197 1.8× 115 1.7× 22 808
Michelle S. Levine United States 9 331 0.6× 495 1.0× 135 0.8× 96 0.9× 56 0.8× 13 697

Countries citing papers authored by Xingcheng Chen

Since Specialization
Citations

This map shows the geographic impact of Xingcheng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingcheng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingcheng Chen more than expected).

Fields of papers citing papers by Xingcheng Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingcheng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingcheng Chen. The network helps show where Xingcheng Chen may publish in the future.

Co-authorship network of co-authors of Xingcheng Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Xingcheng Chen. A scholar is included among the top collaborators of Xingcheng Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingcheng Chen. Xingcheng Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Chen, Xingcheng, et al.. (2025). FGFR4 inhibition augments paclitaxel-induced cell death in ovarian cancer. International Immunopharmacology. 155. 114626–114626.
2.
Zhu, Zhu, Xingcheng Chen, Ming Hu, et al.. (2022). Case report: Significant relief of linezolid-induced peripheral neuropathy in a pre-XDR-TB case after acupuncture treatment. Frontiers in Neurology. 13. 985499–985499.
4.
He, Chunbo, Xiangmin Lv, Cong Huang, et al.. (2019). A Human Papillomavirus-Independent Cervical Cancer Animal Model Reveals Unconventional Mechanisms of Cervical Carcinogenesis. Cell Reports. 26(10). 2636–2650.e5. 46 indexed citations
5.
He, Chunbo, Xiangmin Lv, Cong Huang, et al.. (2019). YAP 1‐ LATS 2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis. EMBO Reports. 20(3). 51 indexed citations
6.
Lv, Xiangmin, Chunbo He, Cong Huang, et al.. (2019). Timely expression and activation of YAP1 in granulosa cells is essential for ovarian follicle development. The FASEB Journal. 33(9). 10049–10064. 91 indexed citations
7.
Zeng, Yongji, Lian Cui, Xingcheng Chen, et al.. (2018). Zyxin promotes colon cancer tumorigenesis in a mitotic phosphorylation-dependent manner and through CDK8-mediated YAP activation. Proceedings of the National Academy of Sciences. 115(29). E6760–E6769. 42 indexed citations
8.
Wang, Zhan, Xingcheng Chen, Shuping Yang, et al.. (2018). Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy. Cellular Signalling. 52. 137–146. 14 indexed citations
9.
He, Chunbo, Xiangmin Lv, Guohua Hua, et al.. (2018). Abstract B43: Disruption of the YAP-LATS2 feedback loop switches ovarian cells from YAP-induced senescence to malignant transformation. Clinical Cancer Research. 24(15_Supplement). B43–B43. 1 indexed citations
10.
Zeng, Yongji, et al.. (2017). Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity. Journal of Biological Chemistry. 292(36). 15028–15038. 19 indexed citations
11.
Stauffer, Seth, et al.. (2017). CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity. Cellular Signalling. 39. 74–83. 27 indexed citations
12.
Chen, Xingcheng, Seth Stauffer, Yuanhong Chen, & Jixin Dong. (2016). Ajuba Phosphorylation by CDK1 Promotes Cell Proliferation and Tumorigenesis. Journal of Biological Chemistry. 291(28). 14761–14772. 41 indexed citations
13.
Chen, Xingcheng, Yuanhong Chen, & Jixin Dong. (2016). MST2 phosphorylation at serine 385 in mitosis inhibits its tumor suppressing activity. Cellular Signalling. 28(12). 1826–1832. 7 indexed citations
14.
He, Chunbo, Dagan Mao, Guohua Hua, et al.. (2015). The Hippo/ YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Molecular Medicine. 7(11). 1426–1449. 211 indexed citations
15.
Yang, Shuping, Lin Zhang, Xingcheng Chen, Yuanhong Chen, & Jixin Dong. (2015). Oncoprotein YAP Regulates the Spindle Checkpoint Activation in a Mitotic Phosphorylation-dependent Manner through Up-regulation of BubR1. Journal of Biological Chemistry. 290(10). 6191–6202. 20 indexed citations
16.
Zhang, Lin, Shuping Yang, Xingcheng Chen, et al.. (2015). The Hippo Pathway Effector YAP Regulates Motility, Invasion, and Castration-Resistant Growth of Prostate Cancer Cells. Molecular and Cellular Biology. 35(8). 1350–1362. 127 indexed citations
17.
Yang, Shuping, Lin Zhang, Vinee Purohit, et al.. (2015). Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 6(34). 36019–36031. 91 indexed citations
18.
Chen, Xingcheng, et al.. (2015). CDK1 phosphorylation of TAZ in mitosis inhibits its oncogenic activity. Oncotarget. 6(31). 31399–31412. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026